6319-95-5

Basic information

• Product Name: 3-MORPHOLIN-4-YL-PROPIONIC ACID HCL
• Synonyms: BUTTPARK 82\11-39;IFLAB-BB F1929-1771;3-MORPHOLIN-4-YL-PROPIONIC ACID HCL;3-MORPHOLIN-4-YL-PROPIONIC ACID HYDROCHLORIDE;SALOR-INT L481122-1EA;OTAVA-BB BB7016234022;3-Morpholin-4-yl-propionicacidxHCl;3-MORPHOLIN-4-YL-PROPIONIC ACID X HCL >98%
• CAS NO: 6319-95-5
• Molecular Formula: C₇H₁₃NO₃*ClH
• Molecular Weight: 195.64
• Mol File: 6319-95-5.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 299.2 °C at 760 mmHg
• Flash Point: 134.8 °C
• Appearance: /
• Vapor Pressure: 0.000286mmHg at 25°C
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 3-MORPHOLIN-4-YL-PROPIONIC ACID HCL(CAS DataBase Reference)
• NIST Chemistry Reference: 3-MORPHOLIN-4-YL-PROPIONIC ACID HCL(6319-95-5)
• EPA Substance Registry System: 3-MORPHOLIN-4-YL-PROPIONIC ACID HCL(6319-95-5)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 6319-95-5(Hazardous Substances Data)

Usage

Chemical Properties

Colorless crystal

InChI:InChI=1/C7H13NO3.ClH/c9-7(10)1-2-8-3-5-11-6-4-8;/h1-6H2,(H,9,10);1H

Upstream product

• 20120-24-5 ethyl 3-morpholinopropionate 

Downstream Products

• 1439391-96-4 C₃₃H₃₉N₇O₆S₂ 
• 1428317-57-0 C₃₅H₄₃I₂N₃O₇ 
• 1314962-43-0 4-acetamidophenyl 3-morpholinopropanoate hydrochloride 
• 944343-02-6 4-amino-6-(4-benzyloxy-3-chloro-phenylamino)-pyrimidine-5-carboxylic acid N'-(3-morpholin-4-yl-propionyl)-hydrazide 

Relevant articles and documents

MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES

Drag derivatives are provided herein which are suitable for loading into liposomal nanoparticle carriers. In some preferred aspects, the derivatives comprise a poorly water-soluble drag derivatized with a weak-base moiety that facilitates active loading of the drag through a LN transmembrane pH or ion gradient into the aqueous interior of the LN. The weak-base moiety can optionally comprise a lipophilic domain that facilitates active loading of the drag to the inner monolayer of the liposomal membrane. Advantageously, LN formulations of the drag derivatives exhibit improved solubility, reduced toxicity, enhanced efficacy, and/or other benefits relative to the corresponding free drags.